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Abstract: The objective of our study is to load first line anti-tubercular drug, 
Isoniazid in chitosan Nanoparticles in order to enhance bioavailability and 
to reduce dose frequency. The chitosan nanoparticles containing the drug 
Isoniazid were prepared by the method of spontaneous emulsification. 
Chitosan gel containing drug is cross linked with Glutaraldehyde and 
nanoparticle suspension obtained was centrifuged at 5000 rpm. It was then 
evaluated for Drug loading, swelling index, Mucoadhesive force, Zeta 
potential, DLs studies, DsC studies, seM studies, In vitro Drug release, 
Pharmacokinetic studies and stability studies.Formulation 1(F1) shows 
maximum Drug Loading, swelling index and mucoadhesive force. The 
positive zeta value was obtained for all formulations due to positive charge 
of polymer used in preparation of dispersion. The DLs plot of Formulations 
shows that average particle diameter are in the range of 661.8-823.8nm. 
The seM study revealed that the micrographs of cross linked chitosan 
nanoparticles have smooth surface. The thermogram of the formulations 
showed the shifting of endotherm. This indicates the possible change in the 
release kinetics and bioavailability of the drug. In vitro drug releases was 
found to be maximum for formulation F6. Pharmacokinetic evaluation shows 
all the formulation shows first order rate release profile and release mechanism 
from nanoparticles is diffusion controlled. stability studies indicated that the 
developed chitosan nanoparticles are physically and chemically stable and 
retain their pharmaceutical properties at various environmental conditions 
over a period of 3 months.





Tuberculosis is a major health problem throughout the world, infecting more 
than 8 million individuals each year. Oral therapy using the currently employed 
anti Tubercular drugs (aTDs) is very effective, but is still associated with a 
number of significant drawbacks. More than 80% of TB cases are of pulmonary 
TB alone and high drug doses are required to be administered because only a 
small fraction of the total dose reaches the lungs after oral administration. aTD 
delivery systems which can be administered via the pulmonary route and can 
avoid the daily dosing, because they would help in: (i) direct drug delivery to 
the diseased organ; (ii) targeting to alveolar macrophages which are used by the 
mycobacteria as a safe site for their prolonged survival; (iii) reduced systemic 
toxicity of the drugs; and (iv) improved patient compliance (v) higher drug 
concentration at the main site of infection. Moreover, in contrast to the oral route 
of administration, inhaled drugs are not subjected to first-pass metabolism. But 
the retention property of liquid or suspension, two commonly used formulations 
in Inhalational method, is not satisfying because they cannot persistently stay 
in the lung. Owing to this limitation, Controlled delivery systems have to be 
studied for Inhalation administration (Kawashime et al 1998).
Drug delivery research is clearly moving from the micro to the nano size 
scale. Nanotechnology is therefore emerging as a field in medicine that is 
expected to elicit significant therapeutic benefits. The development of effective 
nanodelivery systems capable of carrying a drug specifically and safely to a 
desired site of action is one of the most challenging tasks of pharmaceutical 
formulation investigators (sahso et al 2007). Nanoparticles range in size from 
10 to 1000 nm whereas micro- particles lie in the size range of 1 and 1000 
µm. The difference between microparticles and nanoparticles lies not merely in 
the size, but also in the ability of nanoparticles to achieve a high drug loading, 
minimize the consumption of polymers, cross permeability barriers and elicit a 
better therapeutic response (Pandey and Rao et al 2004). Furthermore, inhalable 
nanoparticles stand better chances of mucosal adherence, particle(s) delivery and 
hence net drug delivery to the lungs. a possible obstacle to use nanocarriers for 
pulmonary delivery is that their mass median aerodynamic diameter, an essential 
parameter for the particle deposition in the lungs, is often too small.
a convenient way of delivering drugs to the lungs is the aerosolization 
of the drugs as fine powders with the aid of Dry Powder Inhalers (DPIs). 
alternatively, the drug may be first solubilized/suspended in an aqueous medium 
and subsequently aerosolized (liquid aerosolization or nebulization) through a 
nebulizer. a nebulizer requires a dispersing force (either a jet of gas or ultra- sonic 
waves) for aerosolization. a drug may also be delivered to the lungs directly, 








with a nebulizer, a DPI is more efficient in terms of drug delivery and less time 
consuming. 
Isoniazid is the first line medication in prevention and treatment of tuberculosis. 
It inhibits the synthesis of mycolic acid required for the mycobacterium cell wall. 
INh is less permeated through the stomach and is mainly absorbed through 
the intestine because it occurs in the protonated form at acidic ph (pKa = 2). 
Therefore, it can be considered as a good candidate for the development of a 
site-specific release formulation especially in case of Tuberculosis to deliver it 
in lung. (ahsam et al. 2002, sabitha et al 2010).  Chitosan is a biodegradable, 
biocompatible, cationic hydrophilic polymer with low toxicity, mucoadhesive 
properties, biodegradability and ability to enhance the penetration of large 
molecules across mucosal surfaces obtained through deacetylation of naturally 
occurring chitin. It is also hypoallergenic and has natural antibacterial properties. 
The release modifying and mucoadhesive property of chitosan appears to be a 
good choice for preparing sustained release formulation for lung delivery via 
inhalation (alessandro et al 2009, anne et al 2010).




2. MATERIALS AND METHODS/ EXPERIMENTAL SECTION
Instruments: Instruments used were uV-visible spectrophotometer, FT-IR 
spectrophotometer, sonicator , seM and cellulose dialysis bag.
Materials: all chemicals used were of either analytical or pharmaceutical 
grade, such as
Isoniazid (Micro labs, Banglore)
Chitosan (CIF, Cochin)
span 80 (Loba chemie)
Figure 2: seM photograph of formulation 6.












The chitosan nanoparticles containing the drug isoniazid were prepared by the 
method of spontaneous emulsification which is affordable to do in the laboratory 
setup. Required quantities of chitosan and NaCl (2%) were dispersed in required 
quantities of 3% (v/v) glacial acetic acid and stirred for 2 hours continuously to 
obtain chitosan gel, which was kept overnight to obtain clear chitosan gel. The 
drug was dissolved separately in 5 ml of chitosan gel (drug-to-polymer ratios of 
1:0.5,1:1, 1:1.5, 1:2, 1:2.5, 1:3,1:4 and 1:5) under magnetic stirring. Chitosan 
gel containing the drug was added dropwise into 10 ml of linseed oil containing 
2% vol/vol of span 80 under magnetic stirring. To this 5 mL of acetone were 
added drop by drop (2 ml/ min). The system was maintained under stirring for 1 
hour while covering it with aluminum foil. Then 5 ml glutaraldehyde - saturated 
toluene was slowly added to the system and continuously stirred for 2 hours. The 
nanoparticles suspension obtained was centrifuged at 5000 rpm and washed with 
toluene and dried. Drug-free chitosan nanoparticles were also prepared in the 
same manner by omitting the drug. The entire process was carried out in dark 
room to avoid exposure to sunlight (wilson et al 2010).
4. EVALUATION OF NANOPARTICLES
4.1 Determination of drug-loading capacity
Drug loading was determined by procedure suggested by Barnabas wilson 
et. al. 50 mg of drug-loaded chitosan nanoparticles; these were digested with 




20 mL of a mixture of 0.1 N hCl and ethanol (1:1 v/v) for 24 hours. Then the 
particles were separated by centrifugation at 10,000 rpm, and the drug content 
in the supernatant was analyzed by ultraviolet (uV) spectrophotometry at 262 
nm against dummy nanoparticles, which had also been prepared as reagent 
blanks and treated similarly to the drug-loaded nanoparticles.
Drug Loading Capacity






The prepared product 300 mg was weighed initially (w
d
) and immersed in 250 
mL deionized water at ambient temperature for 24 hours. The swollen weight 
(w
s
) was obtained by gently removing the surface water with blotting paper. 









4.3 Assessment of the mucoadhesive force 
The nanoparticles were immersed in a 50 mL glass beaker at 37 0C containing 
a phosphate buffer solution (ph 7.4) for 5 min in such a way that the solution 
just covered the nanoparticles. after nanoparticles wetting, a round fresh pig 
intestinal mucosa (PIM) with a diameter similar to that of glass beaker was placed 
on nanoparticles surface so as to cover all the nanoparticles and remained for 5 
min in contact with the nanoparticles. The intestinal mucosa with the attached 
nanoparticles was removed and the remaining nanoparticles on the glass beaker 
were dried at 600C till constant weight. The percent of adhered nanoparticles (aN) 











 is the initial weight of nanoparticles and w
t
 the remained unattached 
weight of nanoparticles
4.4 Differential light scattering and zeta potential
Particle size and zeta potential of nanoparticles were measured by using 
Zetasizer nano (Malvern instrument uK) at a fixed angle of 900 using a 








were set as Temperature at 250 C, Viscosity at 0.933 centipoise and index of 
refraction at 1.333. each sample was diluted in distilled water and appropriate 
concentration particle was achieved to avoid multy scattering events. The 
obtained homogenous suspension was examined to determine the volume in 
diameter, size distribution and poly dispersity. each sample is repeated for 3 
times and the values were expressed in mean value. similarly zeta potential 
was measured by same equipment. 
4.5 Scanning electron microscopy
samples were prepared by finely spreading the dried sample of F6, over slabs 
and by drying them under vacuum as a routine procedure. The samples were 
then coated in a cathodic evaporator with a fine gold layer using an ion sputter. 
Coating was provided at 20ma for 4 min. and observed at 520.0 kV in seM 
using a JsM-5581 scanning electron microscope (JeOL, Tokyo, Japan).
4.6 Differential scanning calorimetry
DsC analyses were performed using 821e model instrument from Mettler Toledo 
(schwerzenbach, switzerland). The same was operated using sTaR software 
version 5.21 under solaris operating system. The samples were exposed to a 
heating rate of 100C/min over a temperature range of 30-240C under nitrogen 
purging (80 ml/min) in pin-holed aluminium pans. 
4.7 Invitro release of isoniazid from nanoparticles
The release of the drug Isoniazid from chitosan nanoparticles of different drug-
to-polymer ratios was studied by dialysis method in ph of the body fluid i.e 7.4 
phosphate buffers. 50mg nanoparticles were placed in a cellulose dialysis bag 
which was then sealed at both ends. The dialysis bag was dipped into the receptor 
compartment containing the dissolution medium, which was stirred continuously 
at 100 rpm and maintained at 37°C. The receptor compartment was closed to 
prevent evaporation of the dissolution medium. samples were withdrawn at 
regular time intervals, and the same volume was replaced with fresh dissolution 
medium. The samples were measured by uV spectrophotometry at 262 nm for 
isoniazid against dummy nanoparticles, which had also been prepared as reagent 
blanks and treated similarly to the drug loaded nanoparticles.
4.8 Short Term Stability studies
The samples were taken in borosilicate glass vials and sealed, and the 
vials were stored in room temperature (25°C±2°C/60%Rh± 5%Rh) and 




at 0, 1, 2, and 3 months for their drug content as well as any changes in their 
physical appearance. Chemical stability during the storage was checked Fourier 
transform–infrared (FT-IR) studies after 3 months of storage.
5. RESULTS AND DISCUSSION
The percentage Drug Loading for the all formulation was calculated and the 
result was found to be that all the formulations are varying in the values. 
Formulation 1(F1) shows maximum drug loading of 78.64% and F3 shows 
minimum drug loading of 53.33%. swelling index found to be varying from 
33.03 to 75.57 percentage.Formulation seven (F7) shows minimum value of 
33.03 % .as the concentration of chitosan increases the values of swelling 
index also increased up to 75.57 in formulation one(F1). Mucoadhesive force 
for the all 7 formulation was calculated and the percentage adherence was 
found to be differing in each formulation. The minimum value and maximum 
vales are 98.2% and 99.5% respectively. The zeta potential value was found 
to be in the range of +18.45 to 38.9. The positive zeta value was obtained 
due to positive charge of polymer used in preparation of dispersion. The 
DLs plot of Formulations shows that average particle diameter are in the 
range of 661.8-823.8nm. The size range of nano particle for good pulmonary 
deposition is in the range of 500 to 5000 nm. hence, all the formulations 
are satisfactory for pulmonary deposition. The surface morphology of 
nanoparticles is shown in Figure no: 2. The study revealed that the seM 
micrographs of cross linked chitosan nanoparticles have smooth surface. The 








Figure 5: Release profile from F1, F2, F5,F7.
Figure 6: Release profile from F1, F2, F6
Table 1: Formulation table for Isoniazid nano particles.
Ingredients#
Formulation Code
F1 F2 F3 F4 F5 F6 F7
1:0.5 1:1 1:1.5 1:2 1:3 1:4 1:5
Chitosan (mg) 400 400 400 400 400 400 400
Isoniazid (mg) 200 400 600 800 1200 1600 2000
#every formulation code has: Linseed oil-20ml, span 80-2%, sodium Chloride-




seM micrograph also indicates the aggregation of chitosan microspheres due 
to existing weak interparticle bonding. The thermogram of the formulations 
showed the shifting of endotherm. This indicates the possible change in the 
release kinetics and bioavailability of the drug. In vitro drug releases for the 
formulations were in the range of 76.77-91.39% with formulation F6 having 
the maximum and formulation F7 having the minimum. Pharmacokinetic 
evaluation shows all the formulation shows first order rate release profile 
which suggests that the drug release from nanoparticle depend on drug 
loading. as the best correlation coefficient was observed in higuchi’s plot, 
the major release mechanism from nanoparticles is diffusion controlled 
and follows non- fickian transport as observed by Korsmeyer-Peppas plot. 
stabillity studies were conducted as per ICh guidelines. The results indicated 












F1 78.64 ± 1.572 75.57 ± 1.32 99.1 ± 1.992 23.60±0.012
F2 55.55 ± 1.111 73.04 ± 1.28 98.8 ± 1.972 18.45±0.008
F3 53.33 ± 1.066 69 ± 1.25 98.6 ± 1.982 21.67±0.013
F4 57.18 ± 1.143 66.02 ± 1.15 98.4 ± 1.921 26.98±0.056
F5 59.19 ± 1.183 59.34 ± 1.03 99.5 ± 1.978 31.00±0.016
F6 57.24 ± 1.144 49.40 ± 0.98 98.2 ± 1.996 38.9±0.065
F7 55.52 ± 1.110 33.03 ± 0.57 98.3 ± 1.964 32.78±0.076





In vitro release 
(24 hrs)
F1 67.80 0.362 82.05
F2 68.35 0.260 79.28
F3 66.18 0.384 89.46
F4 72.43 0.379 83.83
F5 66.18 0.384 83.13
F6 82.35 0.193 91.39








that the developed chitosan nanoparticles are physically and chemically 
stable and retain their pharmaceutical properties at various environmental 
conditions over a period of 3 months.
6. CONCLUSION
studies were undertaken on the development and characterization 
of chitosan nanoparticle loaded with isoniazid with a view to develop 
control release formulation. In the preparation of nanoparticle, carrier 
chitosan was used with different concentration of isoniazid and seven 
formulation are made(1:0.5,1:1,1:1.5,1:2,1:3,1:4,1:5). Nanoparticles 
were prepared for all these concentration by spontaneous emulsification 
method. all formulations consist of fine and free flowing powders. 
an interaction study like uV and IR spectra shows that there were no 
interaction between drug and carrier used. seM and DLs studies 
showed that the size of the particles were reduced and formulation 
no 6 having optimum nanonised particles. Zeta potential report also 
shows good positive potentials for formulation no 6 and all formulation 
shows good encapsulation efficiency. DsC studies confirmed the no 
interaction with drug and polymer. as increasing the concentration of 
chitosan the swelling index also increased and all the formulation shows 
good muco adhesive property. Results of dissolution studies shows that 
formulation 6 gives good release profile compared to other formulations. 
Pharmacokinetic evaluation shows all the formulation shows first order 
rate release profile. stability studies including chemical stability studies 
shows that the prepared nano particle is stable for 3 months.
From all these results it concludes that formulation no: 6   is the best 
formulation and which is recommended for future studies like nano dry 
powder preparation and fill in to capsule (rotacaps) and its evaluation.
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